Neural repair function of osteopontin in stroke and stroke‑related diseases (Review)
- Authors:
- Xin Sun
- Chunhao Li
-
Affiliations: Department of Neurosurgery, Yanbian University Affiliated Hospital, Yanbian University, Yanji, Jilin 133000, P.R. China - Published online on: October 16, 2024 https://doi.org/10.3892/etm.2024.12749
- Article Number: 459
-
Copyright: © Sun et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
This article is mentioned in:
Abstract
|
Pinho J, Costa AS, Araújo JM, Amorim JM and Ferreira C: Intracerebral hemorrhage outcome: A comprehensive update. J Neurol Sci. 398:54–66. 2019.PubMed/NCBI View Article : Google Scholar | |
|
Hemphill JC III, Greenberg SM, Anderson CS, Becker K, Bendok BR, Cushman M, Fung GL, Goldstein JN, Macdonald RL, Mitchell PH, et al: Guidelines for the management of spontaneous intracerebral hemorrhage: A guideline for healthcare professionals from the American heart association/American stroke association. Stroke. 46:2032–2060. 2015.PubMed/NCBI View Article : Google Scholar | |
|
Chen D, Zhao Z, Zhang S, Chen S, Wu X, Shi J, Liu N, Pan C, Tang Y, Meng C, et al: Evolving therapeutic landscape of intracerebral hemorrhage: Emerging cutting-edge advancements in surgical robots, regenerative medicine, and neurorehabilitation techniques. Transl Stroke Res: Apr 1, 2024 (Epub ahead of print). | |
|
Yang G, Fan X, Mazhar M, Yang S, Xu H, Dechsupa N and Wang L: Mesenchymal stem cell application and its therapeutic mechanisms in intracerebral hemorrhage. Front Cell Neurosci. 16(898497)2022.PubMed/NCBI View Article : Google Scholar | |
|
Wang F, Jiang M, Chi Y, Huang G and Jin M: Exosomes from circRNA-Ptpn4 can modify ADSC treatment and repair nerve damage caused by cerebral infarction by shifting microglial M1/M2 polarization. Mol Cell Biochem. 479:2081–2092. 2024.PubMed/NCBI View Article : Google Scholar | |
|
Cirillo C, Brihmat N, Castel-Lacanal E, Le Friec A, Barbieux-Guillot M, Raposo N, Pariente J, Viguier A, Simonetta-Moreau M, Albucher JF, et al: Post-stroke remodeling processes in animal models and humans. J Cereb Blood Flow Metab. 40:3–22. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Pikula A, Howard BV and Seshadri S: Stroke and diabetes. In: Cowie CC, Casagrande SS, Menke A, Cissell MA, Eberhardt MS, Meigs JB, Gregg EW, Knowler WC, Barrett-Connor E, Becker DJ, et al (eds). Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases (US), 2018. | |
|
Denhardt DT and Guo X: Osteopontin: A protein with diverse functions. FASEB J. 7:1475–1482. 1993.PubMed/NCBI | |
|
Briones-Orta MA, Avendaño-Vázquez SE, Aparicio-Bautista DI, Coombes JD, Weber GF and Syn W: Osteopontin splice variants and polymorphisms in cancer progression and prognosis. Biochim Biophys Acta Rev Cancer. 1868:93–108.A. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Han X, Wang W, He J, Jiang L and Li X: Osteopontin as a biomarker for osteosarcoma therapy and prognosis. Oncol Lett. 17:2592–2598. 2019.PubMed/NCBI View Article : Google Scholar | |
|
Bandopadhyay M, Bulbule A, Butti R, Chakraborty G, Ghorpade P, Ghosh P, Gorain M, Kale S, Kumar D, Kumar S, et al: Osteopontin as a therapeutic target for cancer. Expert Opin Ther Targets. 18:883–895. 2014.PubMed/NCBI View Article : Google Scholar | |
|
Holm E, Gleberzon JS, Liao Y, Sørensen ES, Beier F, Hunter GK and Goldberg HA: Osteopontin mediates mineralization and not osteogenic cell development in vitro. Biochem J. 464:355–364. 2014.PubMed/NCBI View Article : Google Scholar | |
|
Icer MA and Gezmen-Karadag M: The multiple functions and mechanisms of osteopontin. Clin Biochem. 59:17–24. 2018.PubMed/NCBI View Article : Google Scholar | |
|
Uede T: Osteopontin, intrinsic tissue regulator of intractable inflammatory diseases. Pathol Int. 61:265–680. 2011.PubMed/NCBI View Article : Google Scholar | |
|
Weber GF: The cancer biomarker osteopontin: Combination with other markers. Cancer Genomics Proteomics. 8:263–288. 2011.PubMed/NCBI | |
|
Uaesoontrachoon K, Wasgewatte Wijesinghe DK, Mackie EJ and Pagel CN: Osteopontin deficiency delays inflammatory infiltration and the onset of muscle regeneration in a mouse model of muscle injury. Dis Model Mech. 6:197–205. 2013.PubMed/NCBI View Article : Google Scholar | |
|
Wei R, Wong JPC and Kwok HF: Osteopontin-a promising biomarker for cancer therapy. J Cancer. 8:2173–2183. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Morimoto J, Kon S, Matsui Y and Uede T: Osteopontin; as a target molecule for the treatment of inflammatory diseases. Curr Drug Targets. 11:494–505. 2010.PubMed/NCBI View Article : Google Scholar | |
|
Young MF, Kerr JM, Termine JD, Wewer UM, Wang MG, McBride OW and Fisher LW: cDNA cloning, mRNA distribution and heterogeneity, chromosomal location, and RFLP analysis of human osteopontin (OPN). Genomics. 7:491–502. 1990.PubMed/NCBI View Article : Google Scholar | |
|
Cao H, Cao B, Heazlewood CK, Domingues M, Sun X, Debele E, McGregor NE, Sims NA, Heazlewood SY and Nilsson SK: Osteopontin is An important regulative component of the fetal bone marrow hematopoietic stem cell niche. Cells. 8(985)2019.PubMed/NCBI View Article : Google Scholar | |
|
Lund SA, Wilson CL, Raines EW, Tang J, Giachelli CM and Scatena M: Osteopontin mediates macrophage chemotaxis via α4 and α9 integrins and survival via the α4 integrin. J Cell Biochem. 114:1194–1202. 2013.PubMed/NCBI View Article : Google Scholar | |
|
Standal T, Borset M and Sundan A: Role of osteopontin in adhesion, migration, cell survival and bone remodeling. Exp Oncol. 26:179–184. 2004.PubMed/NCBI | |
|
Boggio E, Dianzani C, Gigliotti CL, Soluri MF, Clemente N, Cappellano G, Toth E, Raineri D, Ferrara B, Comi C, et al: Thrombin cleavage of osteopontin modulates its activities in human cells in vitro and mouse experimental autoimmune encephalomyelitis in vivo. J Immunol Res. 2016(9345495)2016.PubMed/NCBI View Article : Google Scholar | |
|
Clemente N, Raineri D, Cappellano G, Boggio E, Favero F, Soluri MF, Dianzani C, Comi C, Dianzani U and Chiocchetti A: Osteopontin bridging innate and adaptive immunity in autoimmune diseases. J Immunol Res. 2016(7675437)2016.PubMed/NCBI View Article : Google Scholar | |
|
Goncalves DaSilva A, Liaw L and Yong VW: Cleavage of osteopontin by matrix metalloproteinase-12 modulates experimental autoimmune encephalomyelitis disease in C57BL/6 mice. Am J Pathol. 177:1448–1458. 2010.PubMed/NCBI View Article : Google Scholar | |
|
Gimba ER and Tilli TM: Human osteopontin splicing isoforms: Known roles, potential clinical applications and activated signaling pathways. Cancer Lett. 331:11–17. 2013.PubMed/NCBI View Article : Google Scholar | |
|
Leung LL, Myles T and Morser J: Thrombin cleavage of osteopontin and the host anti-tumor immune response. Cancers (Basel). 15(3480)2023.PubMed/NCBI View Article : Google Scholar | |
|
Poggio P, Grau JB, Field BC, Sainger R, Seefried WF, Rizzolio F and Ferrari G: Osteopontin controls endothelial cell migration in vitro and in excised human valvular tissue from patients with calcific aortic stenosis and controls. J Cell Physiol. 226:2139–2149. 2011.PubMed/NCBI View Article : Google Scholar | |
|
Kadoglou NPE, Khattab E, Velidakis N and Gkougkoudi E: The role of osteopontin in atherosclerosis and its clinical manifestations (atherosclerotic cardiovascular diseases)-a narrative review. Biomedicines. 11(3178)2023.PubMed/NCBI View Article : Google Scholar | |
|
Zhao Y, Huang Z, Gao L, Ma H and Chang R: Osteopontin/SPP1: A potential mediator between immune cells and vascular calcification. Front Immunol. 15(1395596)2024.PubMed/NCBI View Article : Google Scholar | |
|
Barizzone N, Marchini M, Cappiello F, Chiocchetti A, Orilieri E, Ferrante D, Corrado L, Mellone S, Scorza R, Dianzani U and D'Alfonso S: Association of osteopontin regulatory polymorphisms with systemic sclerosis. Hum Immunol. 72:930–934. 2011.PubMed/NCBI View Article : Google Scholar | |
|
Carecchio M and Comi C: The role of osteopontin in neurodegenerative diseases. J Alzheimers Dis. 25:179–185. 2011.PubMed/NCBI View Article : Google Scholar | |
|
Comi C, Cappellano G, Chiocchetti A, Orilieri E, Buttini S, Ghezzi L, Galimberti D, Guerini F, Barizzone N, Perla F, et al: The impact of osteopontin gene variations on multiple sclerosis development and progression. Clin Dev Immunol. 2012(212893)2012.PubMed/NCBI View Article : Google Scholar | |
|
Davaanyam D, Kim ID and Lee JK: Intranasal delivery of RGD-containing osteopontin heptamer peptide confers neuroprotection in the ischemic brain and augments microglia M2 polarization. Int J Mol Sci. 22(9999)2021.PubMed/NCBI View Article : Google Scholar | |
|
Topkoru BC, Altay O, Duris K, Krafft PR, Yan J and Zhang JH: Nasal administration of recombinant osteopontin attenuates early brain injury after subarachnoid hemorrhage. Stroke. 44:3189–3194. 2013.PubMed/NCBI View Article : Google Scholar | |
|
Wu J, Zhang Y, Yang P, Enkhjargal B, Manaenko A, Tang J, Pearce WJ, Hartman R, Obenaus A, Chen G and Zhang JH: Recombinant osteopontin stabilizes smooth muscle cell phenotype via integrin receptor/integrin-linked kinase/rac-1 pathway after subarachnoid hemorrhage in rats. Stroke. 47:1319–1327. 2016.PubMed/NCBI View Article : Google Scholar | |
|
Joy MT and Carmichael ST: Encouraging an excitable brain state: Mechanisms of brain repair in stroke. Nat Rev Neurosci. 22:38–53. 2021.PubMed/NCBI View Article : Google Scholar | |
|
Starkey J, Horstick EJ and Ackerman SD: Glial regulation of critical period plasticity. Front Cell Neurosci. 17(1247335)2023.PubMed/NCBI View Article : Google Scholar | |
|
Carmichael ST, Kathirvelu B, Schweppe CA and Nie EH: Molecular, cellular and functional events in axonal sprouting after stroke. Exp Neurol. 287:384–394. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Joy MT, Ben Assayag E, Shabashov-Stone D, Liraz-Zaltsman S, Mazzitelli J, Arenas M, Abduljawad N, Kliper E, Korczyn AD, Thareja NS, et al: CCR5 is a therapeutic target for recovery after stroke and traumatic brain injury. Cell. 176:1143–1157.e13. 2019.PubMed/NCBI View Article : Google Scholar | |
|
Dityatev A and Schachner M: Extracellular matrix molecules and synaptic plasticity. Nat Rev Neurosci. 4:456–468. 2003.PubMed/NCBI View Article : Google Scholar | |
|
Bei F, Lee HHC, Liu X, Gunner G, Jin H, Ma L, Wang C, Hou L, Hensch TK, Frank E, et al: Restoration of visual function by enhancing conduction in regenerated axons. Cell. 164:219–232. 2016.PubMed/NCBI View Article : Google Scholar | |
|
Liu Y, Wang X, Li W, Zhang Q, Li Y, Zhang Z, Zhu J, Chen B, Williams PR, Zhang Y, et al: A sensitized IGF1 treatment restores corticospinal axon-dependent functions. Neuron. 95:817–833.e4. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Liao H, Zou Z, Liu W, Guo X, Xie J, Li L, Li X, Gan X, Huang X, Liu J, et al: Osteopontin-integrin signaling positively regulates neuroplasticity through enhancing neural autophagy in the peri-infarct area after ischemic stroke. Am J Transl Res. 14:7726–7743. 2022.PubMed/NCBI | |
|
Jia J, Yang L, Chen Y, Zheng L, Chen Y, Xu Y and Zhang M: The role of microglial phagocytosis in ischemic stroke. Front Immunol. 12(790201)2022.PubMed/NCBI View Article : Google Scholar | |
|
Devanney NA, Stewart AN and Gensel JC: Microglia and macrophage metabolism in CNS injury and disease: The role of immunometabolism in neurodegeneration and neurotrauma. Exp Neurol. 329(113310)2020.PubMed/NCBI View Article : Google Scholar | |
|
Walker DG and Lue LF: Immune phenotypes of microglia in human neurodegenerative disease: Challenges to detecting microglial polarization in human brains. Alzheimers Res Ther. 7(56)2015.PubMed/NCBI View Article : Google Scholar | |
|
Ladwig A, Walter HL, Hucklenbroich J, Willuweit A, Langen KJ, Fink GR, Rueger MA and Schroeter M: Osteopontin augments M2 microglia response and separates M1- and M2-polarized microglial activation in permanent focal cerebral ischemia. Mediators Inflamm. 2017(7189421)2017.PubMed/NCBI View Article : Google Scholar | |
|
Li G, Oparil S, Kelpke SS, Chen YF and Thompson JA: Fibroblast growth factor receptor-1 signaling induces osteopontin expression and vascular smooth muscle cell-dependent adventitial fibroblast migration in vitro. Circulation. 106:854–859. 2002.PubMed/NCBI View Article : Google Scholar | |
|
Kong L, Li Y, Deng Z, Chen X, Xia Y, Shen B, Ning R, Zhang L and Yin Z: Tibial cortex transverse transport regulates Orai1/STIM1-mediated NO release and improve the migration and proliferation of vessels via increasing osteopontin expression. J Orthop Translat. 45:107–119. 2024.PubMed/NCBI View Article : Google Scholar | |
|
Myers DL, Harmon KJ, Lindner V and Liaw L: Alterations of arterial physiology in osteopontin-null mice. Arterioscler Thromb Vasc Biol. 23:1021–1028. 2003.PubMed/NCBI View Article : Google Scholar | |
|
Ye S, Sun Y, Bie A, Zhou Y, Liu J and Liu Q: Influence of osteopontin short hairpin RNA on the proliferation and activity of rat vascular smooth muscle cells. J Huazhong Univ Sci Technolog Med Sci. 29:144–149. 2009.PubMed/NCBI View Article : Google Scholar | |
|
Dai J, Peng L, Fan K, Wang H, Wei R, Ji G, Cai J, Lu B, Li B, Zhang D, et al: Osteopontin induces angiogenesis through activation of PI3K/AKT and ERK1/2 in endothelial cells. Oncogene. 28:3412–3422. 2009.PubMed/NCBI View Article : Google Scholar | |
|
Edsfeldt A, Swart M, Singh P, Dib L, Sun J, Cole JE, Park I, Al-Sharify D, Persson A, Nitulescu M, et al: Interferon regulatory factor-5-dependent CD11c+ macrophages contribute to the formation of rupture-prone atherosclerotic plaques. Eur Heart J. 43:1864–1877. 2022.PubMed/NCBI View Article : Google Scholar | |
|
Evrard S, Delanaye P, Kamel S, Cristol JP and Cavalier E: SFBC/SN joined working group on vascular calcifications. Vascular calcification: From pathophysiology to biomarkers. Clin Chim Acta. 438:401–414. 2015.PubMed/NCBI View Article : Google Scholar | |
|
Huang K, Chen S, Yu LJ, Wu ZM, Chen QJ, Wang XQ, Li FF, Liu JM, Wang YX, Mao LS, et al: Serum secreted phosphoprotein 1 level is associated with plaque vulnerability in patients with coronary artery disease. Front Immunol. 15(1285813)2024.PubMed/NCBI View Article : Google Scholar | |
|
Wolak T, Sion-Vardi N, Novack V, Greenberg G, Szendro G, Tarnovscki T, Nov O, Shelef I, Paran E and Rudich A: N-terminal rather than full-length osteopontin or its C-terminal fragment is associated with carotid-plaque inflammation in hypertensive patients. Am J Hypertens. 26:326–333. 2013.PubMed/NCBI View Article : Google Scholar | |
|
Ozaki S, Kurata M, Kumon Y, Matsumoto S, Tagawa M, Watanabe H, Ohue S, Higaki J and Ohnishi T: Plasma thrombin-cleaved osteopontin as a potential biomarker of acute atherothrombotic ischemic stroke. Hypertens Res. 40:61–66. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Kadoglou NPE, Gerasimidis T, Golemati S, Kapelouzou A, Karayannacos PE and Liapis CD: The relationship between serum levels of vascular calcification inhibitors and carotid plaque vulnerability. J Vasc Surg. 47:55–62. 2008.PubMed/NCBI View Article : Google Scholar | |
|
Caesar C, Lyle AN, Joseph G, Weiss D, Alameddine FMF, Lassègue B, Griendling KK and Taylor WR: Cyclic strain and hypertension increase osteopontin expression in the Aorta. Cell Mol Bioeng. 10:144–152. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Cheng J, Wu H, Xie C, He Y, Mou R, Zhang H, Yang Y and Xu Q: Single-cell mapping of large and small arteries during hypertensive aging. J Gerontol A Biol Sci Med Sci. 79(glad188)2024.PubMed/NCBI View Article : Google Scholar | |
|
Huynh DTN, Jin Y, Van Nguyen D, Myung CS and Heo KS: Ginsenoside Rh1 inhibits angiotensin ii-induced vascular smooth muscle cell migration and Proliferation through Suppression of the ROS-mediated ERK1/2/p90RSK/KLF4 signaling pathway. Antioxidants (Basel). 11(643)2022.PubMed/NCBI View Article : Google Scholar | |
|
Yu W, Xiao L, Que Y, Li S, Chen L, Hu P, Xiong R, Seta F, Chen H and Tong X: Smooth muscle NADPH oxidase 4 promotes angiotensin II-induced aortic aneurysm and atherosclerosis by regulating osteopontin. Biochim Biophys Acta Mol Basis Dis. 1866(165912)2020.PubMed/NCBI View Article : Google Scholar | |
|
Dziedzic T: Systemic inflammation as a therapeutic target in acute ischemic stroke. Expert Rev Neurother. 15:523–531. 2015.PubMed/NCBI View Article : Google Scholar | |
|
Yan YP, Lang BT, Vemuganti R and Dempsey RJ: Osteopontin is a mediator of the lateral migration of neuroblasts from the subventricular zone after focal cerebral ischemia. Neurochem Int. 55:826–832. 2009.PubMed/NCBI View Article : Google Scholar | |
|
Kalluri HS and Dempsey RJ: Osteopontin increases the proliferation of neural progenitor cells. Int J Dev Neurosci. 30:359–362. 2012.PubMed/NCBI View Article : Google Scholar | |
|
Rogall R, Rabenstein M, Vay S, Bach A, Pikhovych A, Baermann J, Hoehn M, Couillard-Despres S, Fink GR, Schroeter M and Rueger MA: Bioluminescence imaging visualizes osteopontin-induced neurogenesis and neuroblast migration in the mouse brain after stroke. Stem Cell Res Ther. 9(182)2018.PubMed/NCBI View Article : Google Scholar | |
|
Rabenstein M, Hucklenbroich J, Willuweit A, Ladwig A, Fink GR, Schroeter M, Langen KJ and Rueger MA: Osteopontin mediates survival, proliferation and migration of neural stem cells through the chemokine receptor CXCR4. Stem Cell Res Ther. 6(99)2015.PubMed/NCBI View Article : Google Scholar | |
|
Ellison JA, Velier JJ, Spera P, Jonak ZL, Wang X, Barone FC and Feuerstein GZ: Osteopontin and its integrin receptor alpha(v)beta3 are upregulated during formation of the glial scar after focal stroke. Stroke. 29:1698–1707. 1998.PubMed/NCBI View Article : Google Scholar | |
|
Lee H, Jin YC, Kim SW, Kim ID, Lee HK and Lee JK: Proangiogenic functions of an RGD-SLAY-containing osteopontin icosamer peptide in HUVECs and in the postischemic brain. Exp Mol Med. 50(e430)2018.PubMed/NCBI View Article : Google Scholar | |
|
Doyle KP, Yang T, Lessov NS, Ciesielski TM, Stevens SL, Simon RP, King JS and Stenzel-Poore MP: Nasal administration of osteopontin peptide mimetics confers neuroprotection in stroke. J Cereb Blood Flow Metab. 28:1235–1248. 2008.PubMed/NCBI View Article : Google Scholar | |
|
Jin YC, Lee H, Kim SW, Kim ID, Lee HK, Lee Y, Han PL and Lee JK: Intranasal delivery of RGD motif-containing osteopontin icosamer confers neuroprotection in the postischemic brain via αvβ3 integrin binding. Mol Neurobiol. 53:5652–5663. 2016.PubMed/NCBI View Article : Google Scholar | |
|
Chung AG, Frye JB, Zbesko JC, Constantopoulos E, Hayes M, Figueroa AG, Becktel DA, Antony Day W, Konhilas JP, McKay BS, et al: Liquefaction of the brain following stroke shares a similar molecular and morphological profile with atherosclerosis and mediates secondary neurodegeneration in an osteopontin-dependent mechanism. eNeuro. 5(ENEURO.0076-18.2018)2018.PubMed/NCBI View Article : Google Scholar | |
|
Masuda T, Isobe Y, Aihara N, Furuyama F, Misumi S, Kim TS, Nishino H and Hida H: Increase in neurogenesis and neuroblast migration after a small intracerebral hemorrhage in rats. Neurosci Lett. 425:114–119. 2007.PubMed/NCBI View Article : Google Scholar | |
|
Cappellano G, Vecchio D, Magistrelli L, Clemente N, Raineri D, Barbero Mazzucca C, Virgilio E and Dianzani U: The Yin-Yang of osteopontin in nervous system diseases: Damage versus repair. Neural Regen Res. 16:1131–1137. 2021.PubMed/NCBI View Article : Google Scholar | |
|
Spinelli FR, Garufi C, Truglia S, Pacucci VA, Morello F, Miranda F, Perricone C, Ceccarelli F, Valesini G and Conti F: The role of osteopontin as a candidate biomarker of renal involvement in systemic lupus erythematosus. Clin Exp Rheumatol. 37:899–905. 2019.PubMed/NCBI | |
|
Tsai CH, Liu SC, Wang YH, Su CM, Huang CC, Hsu CJ and Tang CH: Osteopontin inhibition of miR-129-3p enhances IL-17 expression and monocyte migration in rheumatoid arthritis. Biochim Biophys Acta Gen Subj. 1861:15–22. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Zhou Y, Yao Y, Sheng L, Zhang J, Zhang JH and Shao A: Osteopontin as a candidate of therapeutic application for the acute brain injury. J Cell Mol Med. 24:8918–8929. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Chen H, Guan B, Chen X, Chen X, Li C, Qiu J, Yang D, Liu KJ, Qi S and Shen J: Baicalin attenuates blood-brain barrier disruption and hemorrhagic transformation and improves neurological outcome in ischemic stroke rats with delayed t-PA treatment: Involvement of ONOO--MMP-9 pathway. Transl Stroke Res. 9:515–529. 2018.PubMed/NCBI View Article : Google Scholar | |
|
Wu B, Ma Q, Suzuki H, Chen C, Liu W, Tang J and Zhang J: Recombinant osteopontin attenuates brain injury after intracerebral hemorrhage in mice. Neurocrit Care. 14:109–117. 2011.PubMed/NCBI View Article : Google Scholar | |
|
Gong L, Manaenko A, Fan R, Huang L, Enkhjargal B, McBride D, Ding Y, Tang J, Xiao X and Zhang JH: Osteopontin attenuates inflammation via JAK2/STAT1 pathway in hyperglycemic rats after intracerebral hemorrhage. Neuropharmacology. 138:160–169. 2018.PubMed/NCBI View Article : Google Scholar | |
|
Sun C, Rahman MSU, Enkhjargal B, Peng J, Zhou K, Xie Z, Wu L, Zhang T, Zhu Q, Tang J, et al: Osteopontin modulates microglial activation states and attenuates inflammatory responses after subarachnoid hemorrhage in rats. Exp Neurol. 371(114585)2024.PubMed/NCBI View Article : Google Scholar | |
|
Zheng J, Wu H, Wang X, Zhang G, Lu J, Xu W, Xu S, Fang Y, Zhang A, Shao A, et al: Temporal dynamics of microglia-astrocyte interaction in neuroprotective glial scar formation after intracerebral hemorrhage. J Pharm Anal. 13:862–879. 2023.PubMed/NCBI View Article : Google Scholar | |
|
Zhang Y, Wang JR, Zhang EN and Zhao ZJ: Analysis of the effect of changes in serum osteopontin levels on patients with acute cerebral infarction. Pak J Med Sci. 40:718–722. 2024.PubMed/NCBI View Article : Google Scholar | |
|
Zhu Z, He Y, Shi M, Guo D, Zhang K, Ren L, Peng Y, Yang P, Chen J, Zang Y, et al: Plasma osteopontin levels and adverse clinical outcomes after ischemic stroke. Atherosclerosis. 332:33–40. 2021.PubMed/NCBI View Article : Google Scholar | |
|
Li HJ, Han NN, Nan Y, Zhang K, Li G and Chen H: Plasma osteopontin acts as a prognostic marker in acute intracerebral hemorrhage patients. Clin Chim Acta. 500:208–212. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Abate MG, Moretto L, Licari I, Esposito T, Capuano L, Olivieri C, Benech A, Brucoli M, Avanzi GC, Cammarota G, et al: Osteopontin in the cerebrospinal fluid of patients with severe aneurysmal subarachnoid hemorrhage. Cells. 8(695)2019.PubMed/NCBI View Article : Google Scholar | |
|
Carbone F, Rigamonti F, Burger F, Roth A, Bertolotto M, Spinella G, Pane B, Palombo D, Pende A, Bonaventura A, et al: Serum levels of osteopontin predict major adverse cardiovascular events in patients with severe carotid artery stenosis. Int J Cardiol. 255:195–199. 2018.PubMed/NCBI View Article : Google Scholar | |
|
Chaitanya V, Devi NH, Suchitra MM, Rao PVLNS, Lakshmi BV and Kumar VS: Osteopontin, cardiovascular risk factors and carotid intima-media thickness in chronic kidney disease. Indian J Nephrol. 28:358–364. 2018.PubMed/NCBI View Article : Google Scholar | |
|
Kurata M, Okura T, Watanabe S, Fukuoka T and Higaki J: Osteopontin and carotid atherosclerosis in patients with essential hypertension. Clin Sci (Lond). 111:319–324. 2006.PubMed/NCBI View Article : Google Scholar | |
|
Elbarbary MR, Ahmed LA, El-Adl DA, Ezzat AA and Nassib SA: Study of osteopontin as a marker of arteriovenous shunt stenosis in hemodialysis patients. Curr Vasc Pharmacol. 22:50–57. 2024.PubMed/NCBI View Article : Google Scholar | |
|
Kadoglou NPE, Gerasimidis T, Kapelouzou A, Moumtzouoglou A, Avgerinos ED, Kakisis JD, Karayannacos PE and Liapis CD: Beneficial changes of serum calcification markers and contralateral carotid plaques echogenicity after combined carotid artery stenting plus intensive lipid-lowering therapy in patients with bilateral carotid stenosis. Eur J Vasc Endovasc Surg. 39:258–265. 2010.PubMed/NCBI View Article : Google Scholar | |
|
Kadoglou NPE, Sailer N, Moumtzouoglou A, Kapelouzou A, Gerasimidis T and Liapis CD: Aggressive lipid-lowering is more effective than moderate lipid-lowering treatment in carotid plaque stabilization. J Vasc Surg. 51:114–121. 2010.PubMed/NCBI View Article : Google Scholar | |
|
Kang N, Ng CS, Hu J, Qiu ZB, Underwood MJ, Jeremy JY and Wan S: Role of osteopontin in the development of neointimal hyperplasia in vein grafts. Eur J Cardiothorac Surg. 41:1384–1389. 2012.PubMed/NCBI View Article : Google Scholar | |
|
Wang X, Louden C, Ohlstein EH, Stadel JM, Gu JL and Yue TL: Osteopontin expression in platelet-derived growth factor-stimulated vascular smooth muscle cells and carotid artery after balloon angioplasty. Arterioscler Thromb Vasc Biol. 16:1365–1372. 1996.PubMed/NCBI View Article : Google Scholar |
